Literature DB >> 10998317

Nucleolin as the earliest target molecule of autoantibodies produced in MRL/lpr lupus-prone mice.

D Hirata1, M Iwamoto, T Yoshio, H Okazaki, J Masuyama, A Mimori, S Minota.   

Abstract

To elucidate the autoantigen against which autoantibodies are produced in the earliest phase of the disease process of systemic lupus erythematosus (SLE), serum samples were collected individually and serially from 10 NZB/NZW F1 and 10 MRL/lpr mice. Using immunoblots with mouse thymoma cell (EL-4) lysates as substrates, all mice were found to generate autoantibody against an either 150-kDa, 110-kDa, 75-kDa, or 55-kDa molecule in as early as 4 weeks. Anti-DNA antibodies occurred almost at the same time or after those against these four molecules. The number of antigens reactive with autoantibodies in immunoblots increased gradually with age. Antibodies against histone molecules were produced after 8 weeks of age. Among the four antigens, the 110-kDa molecule was identified as nucleolin, which is an abundant nucleolar phosphoprotein. Nucleolin binds DNA, RNA, and nucleic acid-binding proteins such as histone H1. Nucleolin is a target of granzyme A of cytotoxic T cells, and autoantibodies against it are found in sera from patients with SLE as well as from those with various viral infections. These results indicate that nucleolin is one of the immunodominant molecules that break down self-tolerance and initiate autoantibody-spreading in a mouse model of SLE. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10998317     DOI: 10.1006/clim.2000.4916

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  9 in total

Review 1.  Evaluation of the highly sensitized transplant recipient.

Authors:  Peter Stastny; Ian-Michael Salvador; Bhavna Lavingia
Journal:  Pediatr Nephrol       Date:  2011-01-22       Impact factor: 3.714

Review 2.  Clinical Significance of Antinucleolar Antibodies: Biomarkers for Autoimmune Diseases, Malignancies, and others.

Authors:  Minoru Satoh; Angela Ceribelli; Tomoko Hasegawa; Shin Tanaka
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-08       Impact factor: 10.817

3.  Nucleolin, a shuttle protein promoting infection of human monocytes by Francisella tularensis.

Authors:  Monique Barel; Karin Meibom; Alain Charbit
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

4.  The GAR/RGG motif defines a family of nuclear alarmins.

Authors:  Shan Wu; Boon Heng Dennis Teo; Seng Yin Kelly Wee; Junjie Chen; Jinhua Lu
Journal:  Cell Death Dis       Date:  2021-05-12       Impact factor: 8.469

5.  HSP70: a promising target for laryngeal carcinoma radiaotherapy by inhibiting cleavage and degradation of nucleolin.

Authors:  Jing Xu; Kangkai Wang; Xin Zhang; Yuanzheng Qiu; Donghai Huang; Wei Li; Xianzhong Xiao; Yongquan Tian
Journal:  J Exp Clin Cancer Res       Date:  2010-08-06

Review 6.  The MRL/lpr mouse strain as a model for neuropsychiatric systemic lupus erythematosus.

Authors:  Maria Gulinello; Chaim Putterman
Journal:  J Biomed Biotechnol       Date:  2011-02-10

7.  Importance of spliceosomal RNP1 motif for intermolecular T-B cell spreading and tolerance restoration in lupus.

Authors:  Fanny Monneaux; Véronique Parietti; Jean-Paul Briand; Sylviane Muller
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

Review 8.  Linking susceptibility genes and pathogenesis mechanisms using mouse models of systemic lupus erythematosus.

Authors:  Steve P Crampton; Peter A Morawski; Silvia Bolland
Journal:  Dis Model Mech       Date:  2014-09       Impact factor: 5.758

9.  Characterisation of a human antibody that potentially links cytomegalovirus infection with systemic lupus erythematosus.

Authors:  Jie Ying Jacklyn Neo; Seng Yin Kelly Wee; Isabelle Bonne; Sen Hee Tay; Manfred Raida; Vojislav Jovanovic; Anna-Marie Fairhurst; Jinhua Lu; Brendon J Hanson; Paul A MacAry
Journal:  Sci Rep       Date:  2019-07-10       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.